분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2012-11-06 13:15:53 , Hit : 2706
 CU-Boulder researchers uncover new target for cancer research




Public release date: 24-Oct-2012
[ Print | E-mail | Share ] [ Close Window ]

Contact: Emilia Costales
emilia.costales@colorado.edu
303-735-3001
University of Colorado at Boulder

In a new paper released today in Nature, BioFrontiers Institute scientists at the University of Colorado Boulder, Tom Cech and Leslie Leinwand, detailed a new target for anti-cancer drug development that is sitting at the ends of our DNA.

Researchers in the two scientists' laboratories collaborated to find a patch of amino acids that, if blocked by a drug docked onto the chromosome end at this location, may prevent cancerous cells from reproducing. The amino acids at this site are called the "TEL patch" and once modified, the end of the chromosome is unable to recruit the telomerase enzyme, which is necessary for growth of many cancerous cells.

"This is an exciting scientific discovery that gives us a new way of looking at the problem of cancer," Cech said. "What is amazing is that changing a single amino acid in the TEL patch stops the growth of telomeres. We are a long way from a drug solution for cancer, but this discovery gives us a different, and hopefully more effective, target."

Cech is the director of the BioFrontiers Institute, a Howard Hughes Medical Investigator and winner of the 1989 Nobel Prize in chemistry.

Co-authors on the study include postdoctoral fellows Jayakrishnan Nandakumar and Ina Weidenfeld; University of Colorado undergraduate student Caitlin Bell; and Howard Hughes Medical Institute Senior Scientist Arthur Zaug.

Telomeres have been studied since the 1970s for their role in cancer. They are constructed of repetitive nucleotide sequences that sit at the ends of our chromosomes like the ribbon tails on a bow. This extra material protects the ends of the chromosomes from deteriorating, or fusing with neighboring chromosome ends. Telomeres are consumed during cell division and, over time, will become shorter and provide less cover for the chromosomes they are protecting. An enzyme called telomerase replenishes telomeres throughout their lifecycles.

Telomerase is the enzyme that keeps cells young. From stem cells to germ cells, telomerase helps cells continue to live and multiply. Too little telomerase produces diseases of bone marrow, lungs and skin. Too much telomerase results in cells that over proliferate and may become "immortal." As these immortal cells continue to divide and replenish, they build cancerous tumors. Scientists estimate that telomerase activation is a contributor in up to 90 percent of human cancers.

To date, development of cancer therapies has focused on limiting the enzymatic action of telomerase to slow the growth of cancerous cells. With their latest discovery, Cech and Leinwand envision a cancer drug that would lock into the TEL patch at chromosome ends to keep telomerase from binding there. This approach of inhibiting the docking of telomerase may be the elegant solution to the complex problem of cancerous cells. Cech, a biochemist, and Leinwand, a biologist, joined forces to work on their latest solution.

"This work was really made possible by the fact that our labs are so close," Leinwand said. "My lab was able to provide the cell biology and understanding of genetics, and Tom's lab allowed us to explore the biochemistry. We have a unique situation at BioFrontiers where labs and people comingle to make discoveries just like this."


###

Leinwand is the chief scientific officer of the BioFrontiers Institute and a professor of molecular, cellular and developmental biology.

Researchers at the University of Colorado have a significant history in developing marketable biotechnologies. Cech founded Ribozyme Pharmaceuticals Inc. Leinwand co-founded Myogen with CU professor Michael Bristow, Hiberna and recently launched MyoKardia.

The BioFrontiers Institute is an interdisciplinary institute housed at the Jennie Smoly Caruthers Biotechnology Building at CU-Boulder. The institute is dedicated to training the next generation of interdisciplinary scientists through its IQ Biology Interdisciplinary Quantitative Biology Ph.D. program. For more information about BioFrontiers visit http://biofrontiers.colorado.edu










687   Biopharma startup raises $51M for therapeutic to treat bleeding complications from angioplasty  이성욱 2012/12/22 2487
686   술 퍼먹게 하는 유전자 있다  이성욱 2012/12/07 2836
685   Glybera Gains Official EMA Nod as First Gene Therapy  이성욱 2012/11/06 2639
684   Genomics: The single life  이성욱 2012/11/06 2088
  CU-Boulder researchers uncover new target for cancer research  이성욱 2012/11/06 2706
682   유럽 첫 유전자 치료제 승인 지단백 리파제 결핍약 '글리베라' 허가  이성욱 2012/11/06 3924
681   Whitehead scientists identify major flaw in standard approach to global gene expression analysis  이성욱 2012/10/29 2201
680   Nobel work boosts drug development  이성욱 2012/10/23 2527
679   유도만능줄기세포, 진짜 만능일까?  이성욱 2012/10/17 2667
678   Early-Earth cells modeled to show how first life forms might have packaged RNA  이성욱 2012/10/16 2532
677   Smallest and fastest-known RNA switches provide new drug targets  이성욱 2012/10/11 2449
676   The Nobel Prize in Physiology or Medicine 2012  이성욱 2012/10/09 2538
675   日 교토대, 쥐 유도만능줄기세포로 난자 만들어  이성욱 2012/10/06 3096
674   “몸매는 날씬해야” 강박관념도 유전자 탓  이성욱 2012/10/04 2636
673   유전자 요법의 후각기능 회복  이성욱 2012/09/12 3086
672   인간 게놈 백과사전 완성: 게놈은 유전자의 단순한 집합체가 아니다  이성욱 2012/09/10 2717
671   자궁경부 암 발생에서 HPV E7의 역할  이성욱 2012/09/10 3646
670   Scientists Design Molecule That Reverses Some Fragile X Syndrome Defects  이성욱 2012/09/07 2528
669   잠 못자는 당신, 알츠하이머병 초기증상?  이성욱 2012/09/07 3618
668   게놈 99% 정크 DNA ‘스위치 역할’  이성욱 2012/09/06 2668

[이전 10개] [1]..[21][22][23][24][25][26][27][28][29] 30 ..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN